R Jude Samulski News Today

Gene therapy legend R. Jude Samulski, Ph.D., co-founder and chief scientific officer of Asklepios BioPharmaceutical (AskBio) since the company was established in 2001, is leaving the CSO job but remaining on the company board.AskBio announced that Mansuo Shannon, Ph.D., becomes CSO effective today. Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, where she also served as CSO.

Preliminary study of messenger RNA therapy against propionic acidaemia shows it is safe, but doubts remain about its usefulness

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms1GenePHIT is a clinical trial to evaluate the safety and efficacy of the one-time administration of AB-1002 and will include the largest number...

A recent article published earlier this month in Frontier in Cellular and Infection Microbiology, recognized R. Jude Samulski, Ph.D., as the most cited and co-cited expert for AAV gene therapy advancements. Here are the details.

A recent article, “Bibliometric analysis of global research trends in adeno-associated virus vector for gene therapy (1991-2022),” published earlier this month in Frontier in Cellular and Infection Microbiology, recognized R. Jude Samulski, Ph.D., as the most cited and co-cited expert for AAV gene therapy advancements.

Viralgen Vector Core welcomes back Andy Holt in new role as Chief Commercial OfficerSAN SEBASTIAN, SPAIN / ACCESSWIRE / October 19, 2023 / Viralgen Vector Core (Viralgen) is pleased to welcome back their previous Executive Vice President of Commercial ...

Trial participants with Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) could benefit from this joint effort to manufacture...

Four oral presentations and seven poster presentations will share insights into AskBios adeno-associated virus research, development and pre-clin...

Viralgen Vector Core (Viralgen), an independently operated subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio), and a member of the Bayer worldwide group of companies, has received Certified Good Manufacturing Practices (cGMP) certification for the manufacture of human medicinal products, investigational ...

-- Certification expands Viralgen's capacity threefold and positions the company as a world-leading CDMO -- -- New facility operates single-use...